阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AZN 阿斯利康

交易中 07-27 12:00:43 EDT

171.02

+1.76

+1.04%

最高173.22	最低167.79	成交量177.46万
今开170.12	昨收169.26	日振幅3.21%
总市值2,653亿	流通市值2,641亿	总股本15.51亿
成交额3.04亿	换手率0.11%	流通股本15.44亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":171.02,"timestamp":1785168040374,"preClose":169.26,"halted":0,"volume":1774591,"delay":0,"changeRate":0.010398203946591158,"floatShares":1544000000,"shares":1551000000,"eps":6.639935,"marketStatus":"交易中","change":1.76,"latestTime":"07-27 12:00:43 EDT","open":170.12,"high":173.22,"low":167.79,"amount":304419994.85625,"amplitude":0.032081,"askPrice":171.09,"askSize":133,"bidPrice":171.01,"bidSize":64,"shortable":3,"etf":0,"ttmEps":6.639935,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1785182400000},"marketStatusCode":2,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NYSE","adjPreClose":169.26,"dividendRate":0.018508,"preHourTrading":{"tag":"盘前","latestPrice":170.25,"preClose":169.26,"latestTime":"09:29 EDT","volume":55901,"amount":9559278.95172,"timestamp":1785158999208,"change":0.99,"changeRate":0.005849,"amplitude":0.049682},"postHourTrading":{"tag":"盘后","latestPrice":168.0101,"preClose":169.26,"latestTime":"19:59 EDT","volume":12570,"amount":2127260.4689,"timestamp":1784937559891,"change":-1.2499,"changeRate":-0.007384,"amplitude":0.007384},"volumeRatio":2.156434,"impliedVol":0.3094,"impliedVolPercentile":0.7729},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2654704827","title":"阿斯利康重申2030年800亿美元营收目标 抗肿瘤药物拉动二季度增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2654704827","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654704827?lang=zh_cn&edition=full","pubTime":"2026-07-27 21:09","pubTimestamp":1785157774,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0289739699.SGD","LU1267930573.SGD","BK4585","LU1829250122.USD","IE00B3T34201.USD","LU0128525929.USD","LU2456880835.USD","LU2468319806.SGD","LU0310800379.SGD","LU2236285917.USD","LU2237443978.SGD","LU2237443895.HKD","LU2462157665.USD","BK4588","LU0889565916.HKD","BK4568","AZNH","LU2417539215.USD","AZN","LU0708994859.HKD","LU0109394709.USD","LU0058720904.USD","LU2237443465.HKD","LU0432979614.USD","LU2237443622.USD","LU2237443382.USD","LU2237443549.SGD","LU0320765992.SGD","BK4007","LU0029864427.USD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654048711","title":"阿斯利康Sone-Ve在晚期胃癌III期试验中显著延长总生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=2654048711","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654048711?lang=zh_cn&edition=full","pubTime":"2026-07-27 21:06","pubTimestamp":1785157560,"startTime":"0","endTime":"0","summary":"阿斯利康今日公布，其潜在同类首创CLDN18.2靶向抗体偶联药物Sone-Ve在III期CLARITY-Gastric01试验中达到主要终点，与研究者选择的治疗方案相比，在二线及后线CLDN18.2阳性晚期胃癌患者中实现了具有统计学显著性和高度临床意义的总生存期改善。晚期胃癌患者预后极差，一线治疗进展后中位生存期仅5-9个月。阿斯利康肿瘤研发执行副总裁Susan Galbraith表示，Sone-Ve有望通过新型靶向ADC替代传统化疗，重塑胃癌治疗格局。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-27/doc-inikhckx3037081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2417539215.USD","LU1829250122.USD","III","LU0029864427.USD","LU0109394709.USD","LU0128525929.USD","BK4588","LU2089984988.USD","LU0058720904.USD","AZNH","LU1267930573.SGD","LU2462157665.USD","BK4134","LU0289739699.SGD","BK4585","LU2456880835.USD","LU0889565916.HKD","BK4568","LU2236285917.USD","LU2237443549.SGD","LU0708994859.HKD","LU0310800379.SGD","LU2237443382.USD","LU2237443895.HKD","IE00B3T34201.USD","LU2237443622.USD","LU2468319806.SGD","LU2237443978.SGD","LU0432979614.USD","AZN","LU2237443465.HKD","LU0320765992.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179671879","title":"盘前异动 | 存储、光通信、半导体板块反弹，闪迪涨近5%，CRDO升超4%，英特尔升近3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179671879","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179671879?lang=zh_cn&edition=full","pubTime":"2026-07-27 16:05","pubTimestamp":1785139537,"startTime":"0","endTime":"0","summary":"7月27日，美股盘前三大股指期货集体上扬，道指期货升0.85%，标普500指数期货升0.86%，纳指期货升1.46%。存储概念股集体上升，闪迪涨近5%；光通信概念股上扬，CRDO升超4%，康宁升超2%；半导体板块普涨，英特尔、美国超微公司升近3%，阿斯麦升超2%；热门中概股盘前上涨，网易涨近2%、京东、阿里巴巴涨近1%；铿腾电子涨超2%；阿斯利康上涨1%，消息面上，阿斯利康第二季度营收增长5%，达153.8亿美元，市场预期为153.9亿美元；调整后每股收益增长18%至2.63美元，好于市场预期的2.48美元，乳腺癌药物Enhertu销售额大幅增长。","market":"us","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"盘前异动 | 存储、光通信、半导体板块反弹，闪迪涨近5%，CRDO升超4%，英特尔升近3%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMUU","SNDC","JD","AZN","MU","BABA","DAMD","KBAB","GLWG","BABO","ASMG","AMDW","AMDG","AMDU","CDNS","SNDG","LINT","BABW","BABX","SNDK","AMDL","MULL","CRDU","AMYY","MUYY","SNDQ","SNXX","WDC","INTW","STX","SNDU","AMDY","ASML","WDCX","BABU","CRDO","KJD","GLW","MUD","MUU","BBYY","AMDD","ASMU","AMD","INTC","NTES","MIC","MUZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654097625","title":"阿斯利康(AZN.US)Q2盈利超预期 市场聚焦新一代抗肿瘤新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2654097625","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654097625?lang=zh_cn&edition=full","pubTime":"2026-07-27 14:54","pubTimestamp":1785135279,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2468319806.SGD","BK4007","BK4588","LU2089984988.USD","LU0708994859.HKD","LU0128525929.USD","LU0889565916.HKD","LU2462157665.USD","LU2237443895.HKD","LU1829250122.USD","LU2456880835.USD","LU2417539215.USD","AZN","AZNH","LU2236285917.USD","LU2237443622.USD","LU0029864427.USD","LU0109394709.USD","BK4568","LU0320765992.SGD","ZECP","LU1267930573.SGD","BK4585","LU2237443978.SGD","LU0058720904.USD","LU2237443465.HKD","LU0310800379.SGD","LU0432979614.USD","LU2237443549.SGD","LU2237443382.USD","LU0289739699.SGD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152178194","title":"异动解读｜阿斯利康夜盘上涨5.33%，第二季度盈利超市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1152178194","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152178194?lang=zh_cn&edition=full","pubTime":"2026-07-27 14:16","pubTimestamp":1785132994,"startTime":"0","endTime":"0","summary":"7月27日，阿斯利康夜盘上涨5.33%，报178.29美元/股，成交额25.17万美元。消息面上，阿斯利康当日公布第二季度财报，核心每股收益为2.63美元，显著高于市场预期的2.48美元，超预期幅度约6%。此前市场一致预期本季度调整后每股收益为2.54美元，同比增长约18%，实际业绩进一步超出乐观预期。值得注意的是，阿斯利康此前因Wainua心脏病药物三期试验失败，股价一度承压下跌近9%，年内累计跌幅约10%。本次业绩超预期有助于缓解市场对其管线执行力的疑虑。","market":"us","thumbnail":"https://static.tigerbbs.com/6a8642475395bb363eacb86148917e7b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6a8642475395bb363eacb86148917e7b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162689726","title":"阿斯利康二季度净利超预期，维持全年业绩展望","url":"https://stock-news.laohu8.com/highlight/detail?id=1162689726","media":"老虎资讯综合","labels":["dataReport","express"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162689726?lang=zh_cn&edition=full","pubTime":"2026-07-27 14:15","pubTimestamp":1785132944,"startTime":"0","endTime":"0","summary":"$阿斯利康$周一公布的第二季度利润超过市场预期，并维持其2026年业绩预测。根据公司汇总的市场预期数据，分析师平均预计阿斯利康第二季度每股利润为2.48美元，销售额为153.9亿美元。阿斯利康继续预计，2026年核心每股收益将实现低双位数百分比增长，总收入将以中高个位数百分比增长。2025年，阿斯利康报告销售额增长约8%，利润增长约11%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/d5876a4e16aa91dcd288f4f89fa9bd02","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/d5876a4e16aa91dcd288f4f89fa9bd02"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿斯利康二季度净利超预期，维持全年业绩展望","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN.UK","AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654941920","title":"阿斯利康第二季度核心每股收益为 2.63 美元，高于预期的 2.48 美元。。","url":"https://stock-news.laohu8.com/highlight/detail?id=2654941920","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654941920?lang=zh_cn&edition=full","pubTime":"2026-07-27 14:01","pubTimestamp":1785132095,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0109394709.USD","LU2237443622.USD","LU2456880835.USD","LU0029864427.USD","BK4588","LU0310800379.SGD","LU2237443382.USD","LU2237443465.HKD","LU1267930573.SGD","AZNH","LU2417539215.USD","BK4007","LU2462157665.USD","LU0432979614.USD","LU2236285917.USD","LU2237443978.SGD","LU2089984988.USD","LU1829250122.USD","LU0708994859.HKD","BK4568","LU0058720904.USD","AZN","LU2468319806.SGD","LU2237443549.SGD","LU0889565916.HKD","LU0128525929.USD","UDN","UUP","LU0320765992.SGD","IE00B3T34201.USD","LU2237443895.HKD","LU0289739699.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190959973","title":"阿斯利康\"魔法\"罕见遇挫：试验失败与股价下跌带来考验","url":"https://stock-news.laohu8.com/highlight/detail?id=1190959973","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190959973?lang=zh_cn&edition=full","pubTime":"2026-07-24 17:00","pubTimestamp":1784883624,"startTime":"0","endTime":"0","summary":"阿斯利康股价今年已下跌10%，两年表现落后于葛兰素史克和更广泛的伦敦股指。目前，市场焦点转向了另外两项晚期临床试验，其结果可能塑造外界对阿斯利康研发引擎及长期增长前景的信心。SERENA-4和AVANZAR是阿斯利康今年预计公布结果的最受关注的晚期肿瘤学试验。阿斯利康在2024年设定了到2030年将年收入提升至800亿美元的目标，并表示预计通过推出约20种新药以及其肿瘤、生物制药和罕见病产品组合的持续增长来实现这一目标。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"阿斯利康\"魔法\"罕见遇挫：试验失败与股价下跌带来考验","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN.UK","AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653712140","title":"阿斯利康(AZN.US)重磅乳腺癌新药在欧盟获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2653712140","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653712140?lang=zh_cn&edition=full","pubTime":"2026-07-23 15:32","pubTimestamp":1784791952,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月23日，阿斯利康宣布，其Etcamah与细胞周期蛋白依赖性激酶4/6抑制剂联合用药已在欧盟获批，用于治疗雌激素受体阳性、HER2阴性的局部晚期或转移性乳腺癌成年患者，前提是检测到ESR1突变，并且在接受一线内分泌治疗联合CDK4/6抑制剂治疗期间未出现疾病进展。阿斯利康表示，Etcamah是目前唯一获批用于乳腺癌一线治疗的新一代口服SERD。此前，该产品已在日本、阿联酋和沙特阿拉伯获批上市，在美国等地区也已递交上市申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471352.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2237443622.USD","BK4007","BK4568","LU2236285917.USD","AZNH","LU0310800379.SGD","FESXmain","BK4588","LU2237443895.HKD","AZN","IE00B3T34201.USD","IPOS","LU0289739699.SGD","LU0432979614.USD","LU0708994859.HKD","LU0128525929.USD","LU0320765992.SGD","LU2456880835.USD","LU2462157665.USD","LU2237443382.USD","LU0058720904.USD","LU0109394709.USD","LU2237443549.SGD","LU2237443978.SGD","LU2468319806.SGD","BK4585","LU0029864427.USD","LU2089984988.USD","FSXEmain","LU0889565916.HKD","LU1267930573.SGD","LU2237443465.HKD","LU1829250122.USD","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653755956","title":"迪哲医药：拟与阿斯利康签署授权许可协议 涉15亿美元款项","url":"https://stock-news.laohu8.com/highlight/detail?id=2653755956","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653755956?lang=zh_cn&edition=full","pubTime":"2026-07-22 17:15","pubTimestamp":1784711725,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2089984988.USD","LU2237443622.USD","LU0708994859.HKD","AZN","IE00B3T34201.USD","LU2237443465.HKD","LU0128525929.USD","LU0889565916.HKD","BK4568","LU1267930573.SGD","LU2237443549.SGD","BK4007","LU0320765992.SGD","LU2236285917.USD","LU2417539215.USD","LU0058720904.USD","LU2237443895.HKD","BK4585","LU2468319806.SGD","LU2462157665.USD","LU2456880835.USD","LU0310800379.SGD","BK4588","AZNH","LU0029864427.USD","159938","LU0289739699.SGD","LU2237443978.SGD","LU0432979614.USD","LU1829250122.USD","LU2237443382.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652216019","title":"阿斯利康：BREZTRI现于美国上市，成为12岁及以上哮喘患者首个且唯一的固定剂量三联疗法。","url":"https://stock-news.laohu8.com/highlight/detail?id=2652216019","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652216019?lang=zh_cn&edition=full","pubTime":"2026-07-20 21:37","pubTimestamp":1784554634,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0058720904.USD","LU0320765992.SGD","LU0109394709.USD","LU2237443978.SGD","LU2237443465.HKD","LU2468319806.SGD","BK4007","LU2462157665.USD","LU0029864427.USD","LU0432979614.USD","LU0889565916.HKD","LU2089984988.USD","LU2456880835.USD","LU2237443622.USD","LU2237443895.HKD","LU2417539215.USD","LU1267930573.SGD","BK4585","AZNH","LU0310800379.SGD","LU1829250122.USD","AZN","IE00B3T34201.USD","IPOS","BK4568","LU2237443382.USD","LU0289739699.SGD","LU0708994859.HKD","LU2236285917.USD","LU0128525929.USD","LU2237443549.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181658661","title":"财报前瞻 ｜阿斯利康本季度营收预计增10.06%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1181658661","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181658661?lang=zh_cn&edition=full","pubTime":"2026-07-20 08:01","pubTimestamp":1784505665,"startTime":"0","endTime":"0","summary":"阿斯利康将于2026年07月27日发布最新季度财报，市场预期收入和盈利保持增长，关注肿瘤与慢病管线进展对盈利的驱动与费用端节奏。一致预期显示，本季度阿斯利康营收预计为154.86亿美元，同比增长10.06%；息税前利润预计为52.02亿美元，同比增长16.16%；调整后每股收益预计为2.54美元，同比增长18.23%。上一季度，阿斯利康营收152.88亿美元，同比增长12.51%；毛利率82.52%；归属于母公司股东的净利润为30.80亿美元，净利率20.15%；调整后每股收益为2.58美元，同比增长3.61%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜阿斯利康本季度营收预计增10.06%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191587427","title":"异动解读｜阿斯利康盘中上涨3.07%，15亿美元引进国产肺癌新药提振市场情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1191587427","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191587427?lang=zh_cn&edition=full","pubTime":"2026-07-15 23:55","pubTimestamp":1784130904,"startTime":"0","endTime":"0","summary":"7月15日，阿斯利康盘中上涨3.07%，报169.4美元/股，成交额1.75亿美元。消息面上，阿斯利康于7月14日宣布与迪哲医药签署全球独家许可协议，以最高15亿美元的总对价获得肺癌药物舒沃哲的全球开发与商业化权益。值得注意的是，迪哲医药7月15日公告提示该协议能否生效仍存不确定性，需经股东会审议及境外反垄断审批。此前阿斯利康因心脏药物三期试验未达主要终点而股价承压，本次交易一定程度上提振了市场对其肿瘤业务的信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651245573","title":"迪哲医药(688192.SH)：与阿斯利康签署的授权许可协议是否能够发生效力存在不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2651245573","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651245573?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:59","pubTimestamp":1784105944,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2462157665.USD","LU2237443622.USD","BK4568","LU2089984988.USD","LU2237443978.SGD","LU0128525929.USD","LU0320765992.SGD","LU0889565916.HKD","LU0432979614.USD","LU2456880835.USD","LU2468319806.SGD","LU2237443895.HKD","BK4007","IE00B3T34201.USD","LU1267930573.SGD","LU0708994859.HKD","LU0289739699.SGD","BK4588","LU1829250122.USD","LU2237443465.HKD","LU2237443382.USD","LU0109394709.USD","LU2237443549.SGD","AZN","LU2417539215.USD","AZNH","LU2236285917.USD","LU0310800379.SGD","BK4585","LU0058720904.USD","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651245568","title":"迪哲医药：股价异常波动 与阿斯利康交易存不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2651245568","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651245568?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:46","pubTimestamp":1784105176,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2237443622.USD","BK4007","BK4568","LU2236285917.USD","AZNH","LU0310800379.SGD","BK4588","LU2237443895.HKD","AZN","IE00B3T34201.USD","LU0432979614.USD","LU0289739699.SGD","LU0708994859.HKD","LU0128525929.USD","LU0320765992.SGD","LU2456880835.USD","LU2462157665.USD","LU2237443382.USD","LU0058720904.USD","LU0109394709.USD","LU2237443549.SGD","LU2237443978.SGD","LU2468319806.SGD","BK4585","LU0029864427.USD","LU2089984988.USD","LU0889565916.HKD","LU1267930573.SGD","LU2237443465.HKD","LU1829250122.USD","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651056891","title":"阿斯利康(AZN)重金引进国产肺癌新药 全面接管全球开发与商业化权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2651056891","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651056891?lang=zh_cn&edition=full","pubTime":"2026-07-14 20:16","pubTimestamp":1784031395,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国际药企巨头阿斯利康 官宣重大药品引进合作，与江苏迪哲医药达成独家授权协议，以6亿美元预付款，拿下后者核心肺癌药物Zegfrovy的全球开发与商业化权益，通过落地国产创新靶向药补强自身肿瘤治疗产品矩阵，完善全球抗肿瘤药物布局体系。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302541","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2456880835.USD","BK4568","LU0058720904.USD","LU2237443895.HKD","LU0320765992.SGD","LU2237443382.USD","LU2417539215.USD","BK4588","LU0109394709.USD","LU2236285917.USD","BK4007","LU2237443622.USD","LU2237443978.SGD","LU2462157665.USD","LU0289739699.SGD","LU1829250122.USD","AZNH","AZN","LU0310800379.SGD","LU0029864427.USD","LU2089984988.USD","IE00B3T34201.USD","LU0708994859.HKD","LU0889565916.HKD","LU0432979614.USD","LU2468319806.SGD","LU0128525929.USD","BK4585","LU1267930573.SGD","LU2237443465.HKD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651122513","title":"14秒，垂直涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2651122513","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651122513?lang=zh_cn&edition=full","pubTime":"2026-07-14 14:06","pubTimestamp":1784009160,"startTime":"0","endTime":"0","summary":"　　7月14日午后，创新药概念异动拉升。个股方面，迪哲医药直线拉升，仅用14秒，封“20CM”涨停，最新市值262.03亿元。此外，哈药股份涨停，实现3连板，辰欣药业、联化科技涨停。　　消息面上，迪哲医药7月14日公告称，公司与阿斯利康签署《许可协议》，授予阿斯利康在全球范围内的独家开发、商业化舒沃哲的权利。　　业绩方面，迪哲医药仍处于亏损阶段，一季度亏损幅度同比收窄。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-07-14/doc-inihuaae8526951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2237443622.USD","BK4007","BK4568","LU2236285917.USD","AZNH","LU0310800379.SGD","BK4588","LU2237443895.HKD","AZN","IE00B3T34201.USD","LU0432979614.USD","LU0289739699.SGD","LU0708994859.HKD","LU0128525929.USD","LU0320765992.SGD","LU2456880835.USD","LU2462157665.USD","LU2237443382.USD","LU0058720904.USD","LU0109394709.USD","LU2237443549.SGD","LU2237443978.SGD","LU2468319806.SGD","BK4585","LU0029864427.USD","LU2089984988.USD","LU0889565916.HKD","LU1267930573.SGD","LU2237443465.HKD","LU1829250122.USD","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651129821","title":"迪哲医药：与阿斯利康签署许可协议 获6亿美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2651129821","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651129821?lang=zh_cn&edition=full","pubTime":"2026-07-14 11:45","pubTimestamp":1784000716,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4568","LU0058720904.USD","LU0320765992.SGD","LU2237443622.USD","LU0029864427.USD","LU1829250122.USD","LU0310800379.SGD","LU2468319806.SGD","LU0109394709.USD","BK4585","LU2237443382.USD","LU2089984988.USD","LU2462157665.USD","LU0289739699.SGD","AZNH","LU1267930573.SGD","BK4588","LU2417539215.USD","LU0708994859.HKD","LU0432979614.USD","AZN","LU2237443549.SGD","LU0128525929.USD","LU0889565916.HKD","IE00B3T34201.USD","LU2237443465.HKD","LU2456880835.USD","LU2236285917.USD","LU2237443895.HKD","LU2237443978.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651419870","title":"贝伦贝格银行将阿斯利康目标股价从每股17000便士下调至16000便士。","url":"https://stock-news.laohu8.com/highlight/detail?id=2651419870","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651419870?lang=zh_cn&edition=full","pubTime":"2026-07-13 13:06","pubTimestamp":1783919186,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2236285917.USD","LU2237443549.SGD","LU0029864427.USD","LU2417539215.USD","LU0320765992.SGD","LU0708994859.HKD","LU0128525929.USD","LU0058720904.USD","BK4588","LU1829250122.USD","LU0310800379.SGD","LU0109394709.USD","BK4585","LU2456880835.USD","LU0889565916.HKD","LU0432979614.USD","LU0289739699.SGD","LU1267930573.SGD","LU2468319806.SGD","LU2237443382.USD","BK4568","LU2089984988.USD","LU2237443465.HKD","LU2237443622.USD","AZN","LU2237443895.HKD","LU2237443978.SGD","AZNH","BK4007","LU2462157665.USD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650168360","title":"石药集团收到阿斯利康就战略合作与授权协议项下的2500万美元研发里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2650168360","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650168360?lang=zh_cn&edition=full","pubTime":"2026-07-12 15:49","pubTimestamp":1783842540,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　石药集团（01093）发布公告，内容有关集团与阿斯利康签订战略合作与授权协议，以利用集团所拥有的长效递送技术平台及多肽药物AI发现平台，开发创新长效多肽药物。董事会欣然宣布，继此前于2026年5月29日收到该协议项下首付款后，集团已于2026年7 月10日收到阿斯利康支付的2500万美元研发里程碑付款。该项里程碑的达成，标志着该协议项下的相关研发工作正按计划稳步推进。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-07-12/doc-inihpuec2906015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1960683339.HKD","BK4585","LU0140636845.USD","LU1152091754.HKD","LU1226287792.SGD","LU2236285917.USD","LU0889565916.HKD","LU1993786604.SGD","LU2089984988.USD","LU2237443382.USD","LU0310800379.SGD","LU0058720904.USD","LU1951186391.HKD","IE00BZ08YR35.GBP","LU1267930573.SGD","BK4007","LU1829250122.USD","IE00B543WZ88.USD","LU1226288170.HKD","LU2039709279.SGD","LU0880133367.SGD","LU0029864427.USD","IE00BZ08YT58.USD","KURE","LU0432979614.USD","01093","IE00B5MMRT66.SGD","LU0289739699.SGD","LU0501845795.SGD","AZN","LU2237443549.SGD","BK1191","LU0320765992.SGD","LU2468319806.SGD","LU2237443465.HKD","LU0315179316.USD","LU1226288253.USD","IE00B031HY20.USD","BK1521","IE00BZ08YS42.EUR","LU2237443895.HKD","LU2237443978.SGD","IE0008369823.USD","LU1226287529.USD","LU1226287875.USD","SG9999004220.SGD","AZNH","LU1008478684.HKD","BK4568","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":-0.0752},{"period":"3month","weight":-0.108},{"period":"6month","weight":-0.0895},{"period":"1year","weight":0.1486},{"period":"ytd","weight":-0.0794}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.515152,"avgChangeRate":0.001662},{"month":2,"riseRate":0.424242,"avgChangeRate":-0.012868},{"month":3,"riseRate":0.545455,"avgChangeRate":0.025511},{"month":4,"riseRate":0.636364,"avgChangeRate":0.028791},{"month":5,"riseRate":0.515152,"avgChangeRate":0.008212},{"month":6,"riseRate":0.470588,"avgChangeRate":0.018421},{"month":7,"riseRate":0.588235,"avgChangeRate":-0.005597},{"month":8,"riseRate":0.484848,"avgChangeRate":0.004788},{"month":9,"riseRate":0.545455,"avgChangeRate":0.001232},{"month":10,"riseRate":0.545455,"avgChangeRate":0.015301},{"month":11,"riseRate":0.515152,"avgChangeRate":0.003764},{"month":12,"riseRate":0.545455,"avgChangeRate":0.007464}],"exchange":"NYSE","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}